Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics

When mitochondria grow abnormally long, leaked RNA may activate anti-tumor immune responses

Researchers from the University of Osaka have demonstrated that mitochondrial hyperfusion, when induced by low levels of DRP1 or cellular stress, activates an immune response through the RIG-I–MAVS pathway. Dependent on the involvement of the BAX protein, the release of mitochondrial RNA into the cytosol enhanced natural killer cell cytotoxicity and reduced tumor growth in a xenograft model. The findings, published in Cell Reports, provide new possibilities for cancer research and treatment.

Mitochondria are constantly dividing and fusing within our cells, reshaping themselves to keep up with the cell’s changing needs. Sometimes, though, things go awry, and mitochondria can grow abnormally long. Are these long mitochondria harmful, or might they serve a purpose?

Mitochondria also act as signaling centers, helping the cell sense and respond to trouble. When mitochondria are hyperfused, for example in the stressed, abnormally long state described above, they release their genetic material into the cytosol, where the cell treats it as a warning sign in the same way it would treat a virus.

Genetic risk for Alzheimer’s disease could depend on how well you sleep

A compelling longitudinal study of over 350 older adults with early beta-amyloid accumulation reveals that the genetic risk for Alzheimer’s disease is not strictly deterministic, but is profoundly modulated by sleep quality through the AQP4 gene—a critical regulator of the brain’s glymphatic waste-clearance system. By cross-referencing specific AQP4 variants with multi-year MRI and PET imaging alongside cognitive assessments, researchers demonstrated that poor sleep parameters, such as shorter duration and delayed onset, significantly accelerate neurodegenerative markers like gray matter loss and ventricle expansion in carriers of specific risk alleles. Paradoxically, however, carriers of certain rare variants exhibited slower cognitive decline even in the presence of sleep disturbances. Ultimately, these findings illuminate a complex gene-environment interplay, proving that identical genetic predispositions can either expedite or buffer against brain atrophy depending on sleep architecture, thereby highlighting the critical necessity of personalized, sleep-targeted lifestyle interventions as a highly actionable strategy for Alzheimer’s prevention.

Scientists have discovered an important link between sleep, genetics, and Alzheimer’s disease. New findings suggest that getting poor sleep can accelerate brain shrinkage and memory loss in older adults carrying specific genetic variants.

Discovery of BIRC3 gene variants in Crohn’s disease yields a druggable pathway

Researchers from The Hospital for Sick Children (SickKids) in Toronto have found a previously unknown genetic cause of Crohn’s disease and uncovered how those changes trigger inflammation through a key immune pathway. The findings, published in Gastroenterology and involving teams from eight countries, will guide more precise treatments and improve the ability to match patients to therapies based on their unique biology.

“We’ve brought together genetics, RNA sequencing, proteomics and more to try for the first time to map the complete disease pathway, and it’s turned into a remarkable precision medicine story,” says lead author Dr. Aleixo Muise, senior scientist in the Cell & Systems Biology program, staff gastroenterologist and co-director of the Inflammatory Bowel Disease (IBD) Centre at SickKids.

“In our SickKids clinic, we want to find the right drug for each person based on their body’s unique signature. That’s why this paper is so exciting: We have pinpointed a druggable pathway.”

3 Age-Reversal Therapies Being Tested Right Now

Most people still think Longevity Escape Velocity is a distant future. But what if some of the technologies that could make it possible are already being tested right now?

In this video, we look at three emerging longevity therapies: partial epigenetic reprogramming, senescent-cell removal, and stem-cell based repair. Some are already in human trials, while others are still early and experimental, but together they show how medicine may begin shifting from treating age-related disease to repairing parts of aging itself.

1:16 — THERAPY #1 — Partial epigenetic reprogramming.
3:34 — THERAPY #2 — SenoVax immune cleanup.
5:24 — THERAPY #3 — Lomecel — B — stem-cell therapy.
7:07 — CONCLUSION — From theory to repair.

📚 SOURCES AND STUDIES MENTIONED

ER-100 / partial epigenetic reprogramming:

Continue reading “3 Age-Reversal Therapies Being Tested Right Now” | >

Inducing cell death in pancreatic cancer cells

Researchers have discovered a previously unknown mechanism that makes most pancreatic cancer cells susceptible to a form of programmed cell death. The team showed that cancer cells with mutations in the KRAS gene develop a vulnerability which can be used to eliminate tumor cells in preclinical models. The findings open up new perspectives for treating pancreatic cancer. The study was published in the journal Nature Communications.

Pancreatic cancer is one of the most aggressive forms of cancer and has so far shown only limited response to available treatments. In approximately 90 percent of cases, these tumors carry mutations in the KRAS gene that drive cancer growth. Due to the ageing population and the lack of effective therapies, physicians, clinicians, and researchers expect pancreatic carcinoma to become one of the leading causes of cancer-related deaths worldwide in the coming years. With the discovery of this newly identified vulnerability, a therapeutically promising approach has now been identified for treating this disease following future clinical trials.

The researchers discovered that KRAS-mutated tumor cells continuously activate signals from the innate immune system. This primes the cancer cells for an inflammatory form of cell death known as necroptosis. In order to survive, tumor cells rely heavily on the protein caspase-8, which usually inhibits necroptosis. If caspase-8 is blocked, the tumor cells die. “KRAS-mutated tumors have a previously unknown Achilles heel,” says the senior author of the study. “By switching off the tumor cells’ defence mechanisms, we can significantly kill these tumors.”

Vascular Control Of Aging And Regeneration (Featuring Anjali Kusumbe, PhD)

Join us on Patreon! / michaellustgartenphd.

Discount Links/Affiliates:
Blood testing (where I get the majority of my labs, for those who blood test with Quest): https://www.ultalabtests.com/partners… those who blood test with LabCorp: https://www.anrdoezrs.net/click-10161… At-Home Metabolomics: https://www.iollo.com?ref=michael-lus… Use Code: CONQUERAGING At Checkout Clearly Filtered Water Filter: https://get.aspr.app/SHoPY Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=… Use Code: CONQUERAGING NAD+ Quantification: https://www.jinfiniti.com/intracellul… Use Code: ConquerAging At Checkout Oral Microbiome: https://www.bristlehealth.com/?ref=mi… Enter Code: ConquerAging SiphoxHealth Blood Testing (ApoB, GrimAge): https://siphoxhealth.com/mlustgarten Green Tea: https://www.ochaandco.com/?ref=fqbtflod Use Code: ML10OFF Diet Tracking: https://shareasale.com/r.cfm?b=139013… If you’d like to support the channel, you can do that with the website, Buy Me A Coffee: https://www.buymeacoffee.com/mlhnrca Conquer Aging Or Die Trying Merch! https://my-store-d4e7df.creator-sprin…

Blood Testing Essentials (Biological Age, CVD-Risk, Kidney Health and Function):
PhenoAge (Biological Age): https://www.ultalabtests.com/partners…

Measure the Bortz biological clock biomarkers: https://www.ultalabtests.com/partners…

Calculate your biological age using the Bortz clock: https://www.longevity-tools.com/human…

Light-triggered arrhythmia reveals rapid brain oxygen shifts in mice

An irregular heartbeat, or arrhythmia, leads to inefficient pumping of blood by the heart, which then prevents blood and oxygen from getting to the body’s other organs. When blood and oxygen flow poorly to the brain, the risk of stroke and cognitive decline increases.

A team of researchers based at Washington University in St. Louis used cardiac optogenetics to noninvasively study arrhythmia and its impact on the brain. Using highly sensitive imaging in a mouse model, they found that arrhythmia in a mouse heart alters oxygen concentration in the brain during and after arrhythmia.

Results of the research are published in Science Advances.

Fragile X deficits in mice respond to gene therapy

A gene therapy designed to replace a missing brain protein restored normal brain activity and improved behavior in a mouse model of fragile X syndrome (FXS), according to a study led by researchers at the University of California, Riverside. The findings, published in Molecular Therapy Nucleic Acids, suggest that gene therapy may one day address the underlying cause of FXS rather than simply treating its symptoms.

FXS affects approximately 2–3% of individuals diagnosed with autism and is one of the best-defined genetic causes of neurodevelopmental disability. The condition occurs when a mutation in the FMR1 gene prevents the production of fragile X messenger ribonucleoprotein (FMRP), a protein that regulates communication between brain cells.

“In a typical brain, FMRP acts like a brake or a volume control,” said Iryna Ethell, the paper’s senior author and a professor of biomedical sciences in the UCR School of Medicine. “Without it, neural circuits become overactive and less efficient, which contributes to many of the developmental and behavioral challenges associated with FXS.”

Scientists uncover a genetic ‘shield’ that lowers the risk of colorectal cancer

A team of scientists from the Barbara Ann Karmanos Cancer Institute, Wayne State University and institutions across the U.S. have published a new paper on the role of TGFBR1*6A, a naturally occurring genetic mutation in the TGFBR1 gene found in approximately 14% of the general population.

The study, “TGFBR1*6A and risk for colorectal cancer,” published June 9, 2026, in Cancer Communications, focuses on TGFBR1*6A and how it influences a person’s risk of developing colorectal cancer. Dr. Boris Pasche, president and CEO of the Karmanos Cancer Institute and chair of the Wayne State University Department of Oncology, was the first to discover TGFBR1*6A as a cancer risk allele.

“This mutation has often been overlooked by genome-wide association study chips, which cannot detect TGFBR1*6A, and is commonly missed by next-generation sequencing platforms due to the complexity of the region,” said Dr. Allan Johansen, a postdoctoral fellow and first author of the paper.

/* */